What it's actually good for
Quercetin is a flavonoid found in onions, apples, capers, and berries, and it's one of the better-studied plant compounds in the anti-inflammatory space — which is a lower bar than it sounds, but it means there's real trial data to look at rather than mechanism papers and marketing copy. The clearest evidence is for reducing inflammatory markers, particularly C-reactive protein. The more exciting claim — that quercetin clears senescent "zombie" cells as a senolytic — rests almost entirely on quercetin paired with the cancer drug dasatinib, not quercetin alone at supplement doses. Those are different products with different evidence, and this review keeps them separate.
What the research says
Anti-inflammatory effects (Grade B). A 2017 meta-analysis by Mohammadi-Sartang and colleagues pooled seven RCTs and found quercetin supplementation significantly lowered circulating CRP, with a weighted mean difference of -0.33 mg/L. The effect was more pronounced at doses of 500 mg/day or higher and, somewhat counterintuitively, in people who started with lower baseline CRP (below 3 mg/L, WMD -0.34 mg/L) rather than those with already-elevated inflammation — a subgroup pattern that fits a modest, general anti-inflammatory effect better than a targeted fix for existing high inflammation. Li et al.'s 2016 review in Nutrients lays out the mechanism: quercetin blocks TNF-driven NF-kB, ERK, and JNK signaling, the same pathways that drive chronic low-grade inflammation. That mechanistic case is strong; the human outcome data (CRP, not hard clinical endpoints like cardiovascular events) is more modest, which is why this sits at a B rather than an A.
Senolytic effects (Grade C). This is where hype outruns evidence. The dasatinib + quercetin (D+Q) combination has been tested in small pilot trials for idiopathic pulmonary fibrosis — a 2019 open-label study of 14 patients (Justice et al., eBioMedicine) found improvements in physical function (faster gait speed, longer 6-minute walk distance) after three weeks of intermittent dosing, but no control group, no change in lung function, and no clear signal in senescence biomarkers. It's feasibility data, not proof of a senolytic effect — and critically, it's the combination with a prescription chemotherapy drug being tested, not quercetin as a standalone supplement. Nobody has shown that quercetin alone, at typical supplement doses, clears senescent cells in humans.
How much, and which form
500-1,000 mg/day is the typical supplemental range, split into one or two doses. The catch is absorption: plain quercetin is poorly water- and fat-soluble, and most of an oral dose never reaches circulation intact. A 2019 pharmacokinetic study (Riva et al.) found that a phytosome formulation — quercetin bound to food-grade lecithin — produced plasma quercetin levels up to 20-fold higher than standard quercetin in the same volunteers. If bioavailability matters for your use case, the phytosome form (or pairing standard quercetin with vitamin C or bromelain, which have weaker but plausible synergy data) is worth the extra cost over plain powder.
Safety & interactions
Quercetin has a solid safety record across human trials — it's one of the more extensively studied flavonoids and is generally well tolerated. Doses above 1 g/day can cause headache or GI upset in some people. It inhibits CYP3A4 and CYP2C9 at higher concentrations, which is relevant if you're on medications metabolized by those enzymes, and it may interact with fluoroquinolone antibiotics and cyclosporine. This is informational, not medical advice — check with a clinician before starting, especially if you're on prescription medication.
How we picked the brand
A quercetin product earns a spot when it addresses the bioavailability problem directly — phytosome technology or co-formulation with absorption enhancers — rather than selling plain quercetin powder at an inflated price, and when it passes independent third-party testing (NSF Certified for Sport or equivalent).